首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Engineering of small interfering RNA-loaded lipidoid-poly( DL -lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach
【24h】

Engineering of small interfering RNA-loaded lipidoid-poly( DL -lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach

机译:小干扰RNA加载的脂质体 - 聚(DL-Lactic-Co-乙醇酸)杂种纳米粒子的工程用于高效和安全的基因沉默:基于设计的方法的质量

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Graphical abstract Display Omitted Abstract Safety and efficacy of therapeutics based on RNA interference, e.g. , small interfering RNA (siRNA), are dependent on the optimal engineering of the delivery technology, which is used for intracellular delivery of siRNA to the cytosol of target cells. We investigated the hypothesis that commonly used and poorly tolerated cationic lipids might be replaced with more efficacious and safe lipidoids as the lipid component of siRNA-loaded lipid-polymer hybrid nanoparticles (LPNs) for achieving more efficient gene silencing at lower and safer doses. However, formulation design of such a complex formulation is highly challenging due to a strong interplay between several contributing factors. Hence, critical formulation variables, i.e. the lipidoid content and siRNA:lipidoid ratio, were initially identified, followed by a systematic quality-by-design approach to define the optimal operating space (OOS), eventually resulting in the identification of a robust, highly efficacious and safe formulation. A 17-run design of experiment with an I-optimal approach was performed to systematically assess the effect of selected variables on critical quality attributes (CQAs), i.e. physicochemical properties (hydrodynamic size, zeta potential, siRNA encapsulation/loading) and the biological performance ( in vitro gene silencing and cell viability). Model fitting of the obtained data to construct predictive models revealed non-linear relationships for all CQAs, which can be readily overlooked in one-factor-at-a-time optimization approaches. The response surface methodology further enabled the identification of an OOS that met the desired quality target product profile. The optimized lipidoid-modified LPNs revealed more than 50-fold higher in vitro gene silencing at well-tolerated doses and approx. a twofold increase in siRNA loading as compared to reference LPNs modified with the commonly used cationic lipid dioleyltrimethylammonium propane (DOTAP). Thus, lipidoid-modified LPNs show highly promising prospects for efficient and safe intracellular delivery of siRNA.
机译:图解摘要显示省略了基于RNA干扰的治疗方法的抽象安全性和有效性,例如, ,小干扰RNA(siRNA),取决于递送技术的最佳工程,其用于细胞内递送siRNA至靶细胞的细胞溶胶。我们调查了常用和耐受性差异的阳离子脂质的假设可以用更有效和安全的脂质体作为siRNA负载的脂质 - 聚合物杂化纳米颗粒(LPN)的脂质组分代替,用于在较低和更安全的剂量下实现更有效的基因沉默。然而,由于几种贡献因素之间的强烈相互作用,这种复杂配方的配方设计具有高度挑战性。因此,最初鉴定了临界制剂变量,即脂质化含量和siRNA:脂质化比例,然后是一种系统的质量逐个设计方法来定义最佳操作空间(OOS),最终导致识别强大的,高度有效和安全的配方。进行17次运行具有I-Optimal方法的实验设计,以系统地评估所选变量对关键质量属性(CQAS)的影响,即物理化学性质(流体动力大小,Zeta电位,siRNA封装/装载)以及生物学性能(体外基因沉默和细胞活力)。所获得的数据的模型拟合构建预测模型显示所有CQA的非线性关系,这可以很容易地忽略在一个因素 - AT-TIME优化方法中。响应表面方法进一步使得能够识别符合所需质量目标产品简档的OOS。优化的脂质化改性的LPN显示在耐受良好的剂量和大约50倍的体外基因中透露超过50倍。与常用阳离子脂质二氧酰二甲基丙烷(DOTAP)改性的参考LPN相比,siRNA负载的两倍增加。因此,脂质化改性的LPN显示出高效和安全的siRNA细胞内递送的前景。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号